VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP-I) in patients with metastatic adenocarcinoma of the lung

R. T. Eagan, E. T. Creagan, J. N. Ingle, J. Rubin, S. Frytak, L. K. Kvols, T. R. Fleming

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalTumori
Volume65
Issue number1
StatePublished - 1979

Fingerprint

Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Survival
Adenocarcinoma of lung
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Eagan, R. T., Creagan, E. T., Ingle, J. N., Rubin, J., Frytak, S., Kvols, L. K., & Fleming, T. R. (1979). VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP-I) in patients with metastatic adenocarcinoma of the lung. Tumori, 65(1), 105-109.

VP-16, cyclophosphamide, adriamycin and cis-platinum (V : CAP-I) in patients with metastatic adenocarcinoma of the lung. / Eagan, R. T.; Creagan, E. T.; Ingle, J. N.; Rubin, J.; Frytak, S.; Kvols, L. K.; Fleming, T. R.

In: Tumori, Vol. 65, No. 1, 1979, p. 105-109.

Research output: Contribution to journalArticle

Eagan, RT, Creagan, ET, Ingle, JN, Rubin, J, Frytak, S, Kvols, LK & Fleming, TR 1979, 'VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP-I) in patients with metastatic adenocarcinoma of the lung', Tumori, vol. 65, no. 1, pp. 105-109.
Eagan RT, Creagan ET, Ingle JN, Rubin J, Frytak S, Kvols LK et al. VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP-I) in patients with metastatic adenocarcinoma of the lung. Tumori. 1979;65(1):105-109.
Eagan, R. T. ; Creagan, E. T. ; Ingle, J. N. ; Rubin, J. ; Frytak, S. ; Kvols, L. K. ; Fleming, T. R. / VP-16, cyclophosphamide, adriamycin and cis-platinum (V : CAP-I) in patients with metastatic adenocarcinoma of the lung. In: Tumori. 1979 ; Vol. 65, No. 1. pp. 105-109.
@article{6e9707a596ed414998342a66f4d589d5,
title = "VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP-I) in patients with metastatic adenocarcinoma of the lung",
abstract = "In an attempt to improve upon the 42{\%} regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5{\%} (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35{\%} (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.",
author = "Eagan, {R. T.} and Creagan, {E. T.} and Ingle, {J. N.} and J. Rubin and S. Frytak and Kvols, {L. K.} and Fleming, {T. R.}",
year = "1979",
language = "English (US)",
volume = "65",
pages = "105--109",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - VP-16, cyclophosphamide, adriamycin and cis-platinum (V

T2 - CAP-I) in patients with metastatic adenocarcinoma of the lung

AU - Eagan, R. T.

AU - Creagan, E. T.

AU - Ingle, J. N.

AU - Rubin, J.

AU - Frytak, S.

AU - Kvols, L. K.

AU - Fleming, T. R.

PY - 1979

Y1 - 1979

N2 - In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

AB - In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

UR - http://www.scopus.com/inward/record.url?scp=0018772474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018772474&partnerID=8YFLogxK

M3 - Article

C2 - 442215

AN - SCOPUS:0018772474

VL - 65

SP - 105

EP - 109

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -